Jul 28, 2009 (Datamonitor via COMTEX) -- Swiss pharmaceutical group Novartis has reported that the EU’s Committee on Human Medicinal Products has issued a positive opinion recommending the approval of Ilaris for cryopyrin-associated periodic syndrome or CAPS, a fatal auto-inflammatory disease.
